Literature DB >> 11561096

Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems.

I Fedorova1, A Hashimoto, R A Fecik, M P Hedrick, L O Hanus, D L Boger, K C Rice, A S Basile.   

Abstract

While the endogenous fatty acid amide oleamide has hypnotic properties, neither the breadth of its behavioral actions nor the mechanism(s) by which these behaviors may be mediated has been elucidated. Therefore, the effects of oleamide on the performance of rats in tests of motor function, analgesia, and anxiety were investigated. Oleamide reduced the distance traveled in the open field (ED50 = 14, 10-19 mg/kg, mean, 95% confidence interval), induced analgesia and hypothermia, but did not cause catalepsy. Moreover, a dose of oleamide without effect on motor function was anxiolytic in the social interaction test and elevated plus-maze. These actions of a single dose of oleamide lasted for 30 to 60 min. While rats became tolerant to oleamide following 8 days of repeated administration, oleamide is a poor inducer of physical dependence. Pretreatment with antagonists of the serotonin (5HT)1A, 5HT2C, and vanilloid receptors did not modify oleamide's effects. However, the cannabinoid receptor antagonist SR 141716A inhibited oleamide-induced analgesia in the tail-flick assay, the gamma-aminobutyric acid (GABA)A receptor antagonist bicuculline reversed the analgesia and hypothermia, and the dopamine D2 receptor antagonist L 741626 blocked oleamide's locomotor and analgesic actions. Interestingly, oleamide analogs resistant to hydrolysis by fatty acid amide hydrolase (FAAH) maintained but did not show increased behavioral potency or duration of action, whereas two FAAH inhibitors produced analogous behavioral effects. Thus, oleamide induces behaviors reminiscent of the actions of endogenous cannabinoids, but the involvement of GABAergic and dopaminergic systems, either directly or indirectly, in the actions of oleamide cannot be ruled out.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11561096

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

1.  Evaluation of fatty acid amides in the carrageenan-induced paw edema model.

Authors:  Laura E Wise; Roberta Cannavacciulo; Benjamin F Cravatt; Billy F Martin; Aron H Lichtman
Journal:  Neuropharmacology       Date:  2007-06-22       Impact factor: 5.250

Review 2.  The expanding field of cannabimimetic and related lipid mediators.

Authors:  Heather B Bradshaw; J Michael Walker
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

Review 3.  Fatty acid amide signaling molecules.

Authors:  Cyrine Ezzili; Katerina Otrubova; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2010-08-13       Impact factor: 2.823

4.  N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice.

Authors:  Giulia Donvito; Fabiana Piscitelli; Pretal Muldoon; Asti Jackson; Rosa Maria Vitale; Enrico D'Aniello; Catia Giordano; Bogna M Ignatowska-Jankowska; Mohammed A Mustafa; Francesca Guida; Gavin N Petrie; Linda Parker; Reem Smoum; Laura Sim-Selley; Sabatino Maione; Aron H Lichtman; M Imad Damaj; Vincenzo Di Marzo; Raphael Mechoulam
Journal:  Neuropharmacology       Date:  2018-03-19       Impact factor: 5.250

5.  Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH).

Authors:  Xiaoshan Min; Stephen T Thibault; Amy C Porter; Darin J Gustin; Timothy J Carlson; Haoda Xu; Michelle Lindstrom; Guifen Xu; Craig Uyeda; Zhihua Ma; Yihong Li; Frank Kayser; Nigel P C Walker; Zhulun Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

Review 6.  Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

7.  Metabolite Profiling of 5'-AMP-Induced Hypometabolism.

Authors:  Zhaoyang Zhao; Anita Van Oort; Zhenyin Tao; William G O'Brien; Cheng Chi Lee
Journal:  Metabolomics       Date:  2014-02-01       Impact factor: 4.290

8.  Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors.

Authors:  James D Leggett; S Aspley; S R G Beckett; A M D'Antona; D A Kendall; D A Kendall
Journal:  Br J Pharmacol       Date:  2004-01-05       Impact factor: 8.739

9.  Serum global metabolomics profiling reveals profound metabolic impairments in patients with MPS IIIA and MPS IIIB.

Authors:  Haiyan Fu; Aaron S Meadows; Ricardo J Pineda; Robert P Mohney; Steve Stirdivant; Douglas M McCarty
Journal:  Metab Brain Dis       Date:  2017-04-05       Impact factor: 3.584

10.  The serotonergic system may be involved in the sleep-inducing action of oleamide in rats.

Authors:  Jing-Yu Yang; Chun-Fu Wu; Fang Wang; Hong-Rui Song; Wen-Jun Pan; Yu-Ling Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-13       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.